Adult Osteogenic Sarcoma

James J. Stark, MD, FACP

Medical Director, Cancer Program and Director of Palliative Care
Maryview Medical Center

Professor of Medicine
Eastern Virginia Medical School
Case Presentation

- 34 y.o. man had hip pain for three months, put off having x-rays done
- Felt his hip “pop” while working as a plumber; no real trauma
- Quickly developed excruciating pain
- X-ray: fracture of right femoral head...pathologic fracture with benefit of hindsight
- Underwent nailing of hip
- Post-op X-ray....
Abnormal part of bone
Case Presentation, continued

- Upon admission had undergone urinary drug screen: positive for LSD, benzodiazepines, opiates, amphetamines
- Continued to complain of pain post-op; question of drug-seeking behavior raised
- Two months later nails started working their way out of bone; bone fragments shifted; orthopedic surgeon temporized
Case Presentation, cont.

• Sought second orthopedic opinion
• Underwent total hip replacement
• Pathology: Telangiectatic Osteogenic Sarcoma
• Examples....
AND NOW FOR PATHOLOGY...
Osteosarcoma

- At least focal osteoid production by neoplastic cells
- Conventional intramedullary
  - Osteoblastic, Chondroblastic, Fibroblastic, Giant cell rich, MFH-like
- Other patterns are less common
Case, continued

- Referred to tertiary-care cancer center for therapy; upon arrival was noted to have tiny pulmonary metastases and additional bone lesions
- Chemotherapy started: lung metastases regressed, bone lesions worsened (raising question of multi-focal osteosarcoma)
- Died fifteen months after diagnosis of overwhelming metastatic disease
Osteogenic Sarcoma

Terry Fox: developed OS at age 18 in 1976, ran across Canada to publicize his illness, died of lung metastases before he could finish.

Voted Canada’s most famous citizen of the 20th century

Who is this?
Characteristics of O.S.

- Typically a disease of adolescents
- Typically develops in distal femur or proximal tibia, but site can vary...
- Typical X-rays...
Typical X-rays in Osteogenic Sarcoma

Pathologic fracture in O.S.
Clinical Spectrum of O.S.

- 400 cases/year in U.S.A.
- Typically between ages 13 and 16

Gurney, JG, et SEER Program 1975-1995
Characteristics of O.S.

• Bimodal distribution (second peak over age 65)

• Epidemiology:
  – Can arise in area of previous irradiation up to 40 years later (average 15 yrs)
  – Risk may be heightened by concomitant chemotherapy
  – Can arise in area of long-standing Paget’s disease (rare)
  – Genetic diseases which predispose to O.S......
Genetic Predisposition to O.S.

- Hereditary retinoblastoma
- Li-Fraumeni Syndrome
  - Variety of cancers associated with mutation of P-53 tumor suppressor gene
- Rothmund-Thomson Syndrome (Poikiloderma Congenitale)
- Bloom and Werner Syndromes
  - Last 3 associated with mutation of RecQ gene group
History of the Treatment of O.S.

- Pre-chemotherapy era (before 1970)
  - 80-90% of patients died, most relapsing in the first 12-18 months after diagnosis

- In early 1970’s principles of cancer chemotherapy were applied to patients with newly diagnosed disease primarily in the adjuvant setting (immediately after definitive surgery) to eradicate microscopic metastases
  - Data since then, primarily derived from study of disease in adolescence:
    - 70% survival if chemo started before overt metastasis
    - 50% of patients with limited lung metastases can be cured with thoracotomy plus chemotherapy
    - 25% of patients with advanced metastatic disease can be cured with chemotherapy alone
Closer Look at Impact of Adjuvant Chemotherapy

- Naysayers criticized outcomes data because of improved index of suspicion and earlier diagnosis in general.
- Mayo Clinic investigators reported survival increase from 20 to 50% between 1960 and 1975 with earlier diagnosis alone.*
- Rarity of disease made it difficult to do randomized control trials to assess impact of chemo on cure rate.
- Best series finally published in 1987, fifteen years after therapy began…

Eilber randomized trial from UCLA*

- 59 patients randomized: 32 treated, 27 observed
- Groups matched for age, gender, location of tumor
- Median age 16
- All patients received pre-op intra-arterial chemo and radiation; randomization occurred after surgery (curious design!)
- Limb salvage done where feasible; same percentage in control and post-op chemo groups
- Post-op chemo complex and included high-dose methotrexate and leucovorin rescue

Disease-Free Survival

- Cumulative % Free of Recurrence
- Months Post-Operative
- N=32
- N=27
- N=18
- P=0.004
- CONTROL
- T-10 B
Overall Survival

- Cumulative % Survival
  - P = 0.003
  - N = 32
  - N = 27

- Months Post-Operative
  - Median
Question of survival drift explored

- Patients from the 1970’s who received no chemotherapy either before or after surgery were compared to control group in study…
Survival drift

Calls into question value of neo-adjuvant intra-arterial chemo

Tends to refuse key Mayo Clinic assertion that natural history of disease was changing because of earlier diagnosis.
Predictors of Survival

• Memorial Sloan Kettering Cancer Center retrospective analysis of results*

• Looked at:
  – Value of pre-operative chemotherapy;
  – Survival with amputation versus limb-sparing surgery
  – Histologic response to pre-op chemo as predictor of survival
  – Site of primary tumor as predictor of survival
  – Influence of age at diagnosis on outcome

Value of Pre-Operative Intra-Arterial Chemotherapy

No significant difference ($p=0.29$) between groups
Amputation versus Limb Salvage

\[ P = 0.34 \text{ (N.S.)} \]
Impact of Response to Pre-Op Chemo

- Excellent response
- No response

[Graph showing survival rates with marks indicating time in months and proportion alive & disease-free]
Importance of Site of Primary

Proximal tibia

Axial skeleton
Significance of Age at Diagnosis

[Graph showing the proportion alive and disease-free over time for different age groups: <12, 12-21, >21 months.]
What About Osteosarcoma in Adults?

• Best data from Korean study*
• Looked at survival in patients younger and older than 40
• Looked at primary tumor sites in older patients

Jeon study, continued

Table 2. Statistically significant comparisons between older patients and adolescent patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Older patients</th>
<th>Adolescent patients</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extremity</td>
<td>31 (79.5%)</td>
<td>41 (95.3%)</td>
<td>0.035</td>
</tr>
<tr>
<td>Axial Bone</td>
<td>8 (20.5%)</td>
<td>2 (4.7%)</td>
<td></td>
</tr>
<tr>
<td>Radiological findings</td>
<td></td>
<td></td>
<td>0.031</td>
</tr>
<tr>
<td>Osteolytic</td>
<td>19/29 (65.5%)</td>
<td>10/43 (23.3%)</td>
<td></td>
</tr>
<tr>
<td>Osteoblastic</td>
<td>3/29 (10.4%)</td>
<td>27/43 (62.8%)</td>
<td></td>
</tr>
<tr>
<td>Mixed</td>
<td>7/29 (24.1%)</td>
<td>5/43 (13.9%)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy-induced tumor necrosis</td>
<td>3 (16.7%)</td>
<td>18 (42.2%)</td>
<td>0.035</td>
</tr>
<tr>
<td>Good responder</td>
<td>15 (83.3%)</td>
<td>25 (57.8%)</td>
<td></td>
</tr>
<tr>
<td>Poor responder</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pathologic Fracture

• Our patient presented with pathologic fracture
  – Can you still save the limb after fracture?
  – If so, does this impact adversely the outcome?
  – What is the overall impact of fracture on outcome?
Confidence limits overlap

Difference not significant

Survival with and without Fracture

Difference highly significant
Conclusions

• Pre-Op intra-arterial chemotherapy yields in-vivo evidence of chemo sensitivity and predicts for, but does not affect, outcome.
• Post-Op chemo has markedly enhanced survival.
• Limb salvage is possible and does not worsen outcome.
• Adults, especially those with presentation in atypical location, do much worse than adolescents with typical O.S.
• Fracture (as seen in our patient) predicts for a bad outcome.
New Office of StarkOncology

Visit our practice at www.StarkOncology.com
where you can view a copy of this talk